Learn more

Hyderabad [India], March 24 (ANI): Bharat Biotech International Ltd has started clinical trials of the Tuberculosis vaccine MTBVAC on adults in India, the company said on Sunday. As per Bharat Biotech, MTBVAC is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, Biofabri. The trials are being carried out by Bharat Biotech in close collaboration with Biofabri. Trials to evaluate the safety and immunogenicity of MTBVAC have started with a pivotal safety, immunogenicity and efficacy trial planned to start in 2025. The official release from…

cuu